AKT1 and gastric adenocarcinoma: Wang et al. found that in dMMR gastric adenocarcinoma, a higher mutation burden in the PI3K–AKT–mTOR pathway correlated with reduced immune cell infiltration and inferior response to immune checkpoint inhibitors [26].